Balance Sheet

Accounts Payables Assets Cash & Current Investments Cash & Equivalents Common Equity Current Assets Current Leases Current Taxes Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Liabilities from Discontinued Operations Long-Term Deferred Tax Long-Term Investments Minority Interest Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Sanofi (SNY) Convertible Debt (2020 - 2021)

Sanofi's Convertible Debt history spans 2 years, with the latest figure at $24.4 billion for Q2 2021.

On a quarterly basis, Convertible Debt changed N/A to $24.4 billion in Q2 2021 year-over-year; TTM through Jun 2021 was $24.4 billion, a N/A change, with the full-year FY2020 number at $27.0 billion, changed N/A from a year prior.
Convertible Debt hit $24.4 billion in Q2 2021 for Sanofi, down from $27.0 billion in the prior quarter.
Over the last five years, Convertible Debt for SNY hit a ceiling of $27.0 billion in Q4 2020 and a floor of $24.4 billion in Q2 2021.